首页> 外文期刊>Investigative ophthalmology & visual science >Topical nepafenac inhibits ocular neovascularization.
【24h】

Topical nepafenac inhibits ocular neovascularization.

机译:局部奈帕芬酸抑制眼新血管形成。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Topical nepafenac readily penetrates the cornea and is metabolized to amfenac, a potent cyclooxygenase (COX)-1 and COX-2 inhibitor. In this study, we tested the effect of topical nepafenac in three murine models of ocular neovascularization (NV). METHODS: A masked trial was performed to compare the topical effects of vehicle with one of several concentrations of nepafenac (0.01%, 0.03%, 0.1%, or 0.5%), 0.1% diclofenac, or 0.5% ketorolac tromethamine in mice with oxygen-induced ischemic retinopathy, mice with choroidal NV (CNV) due to laser-induced rupture of Bruch's membrane, or transgenic mice with increased expression of vascular endothelial growth factor (VEGF) in photoreceptors (rho/VEGF transgenic mice). RESULTS: Mice treated with 0.1% or 0.5% nepafenac had significantly less CNV and significant less ischemia-induced retinal NV than did vehicle-treated mice. Nepafenac also blunted the increase in VEGF mRNA in the retina induced by ischemia. In rho/VEGF transgenic mice, nepafenac failed toinhibit neovascularization. In additional studies, compared with vehicle-treated mice, mice treated with 0.1% or 0.03% nepafenac had significantly less CNV, whereas eyes treated with 0.1% diclofenac showed no significant difference. Mice treated with 0.5% ketorolac tromethamine for 14 days had high mortality, but when evaluated after 7 days of treatment showed no difference from mice treated with vehicle for 7 days. CONCLUSIONS: Topical nepafenac inhibits CNV and ischemia-induced retinal neovascularization by decreasing production of VEGF. The absence of effect in rho/VEGF transgenic mice is consistent with this mechanism. Topical nepafenac may provide an effective new treatment for ocular neovascularization. The excellent corneal penetration of nepafenac certainly plays an important role in this effect. It is possible that other antiangiogenic agents are also amenable to topical application after formulations are identified that maximize their corneal penetration. Because of the many advantages of the topical route of delivery, this is a possible topic for exploration.
机译:用途:局部尼帕芬酸容易穿透角膜并被代谢为有效的环氧合酶(COX)-1和COX-2抑制剂氨苯丙酸。在这项研究中,我们在三种鼠眼新血管形成(NV)模型中测试了局部nepafenac的作用。方法:进行了一项掩盖试验,以比较载剂与几种浓度的奈帕芬酸(0.01%,0.03%,0.1%或0.5%),0.1%双氯芬酸或0.5%酮咯酸三甲胺中的一种的局部作用。诱导的缺血性视网膜病变,由于激光诱导的Bruch膜破裂而产生脉络膜NV(CNV)的小鼠,或在感光细胞中表达血管内皮生长因子(VEGF)的转基因小鼠(rho / VEGF转基因小鼠)。结果:与媒介物治疗的小鼠相比,用0.1%或0.5%的奈帕芬酸治疗的小鼠的CNV显着减少,缺血诱导的视网膜NV显着减少。 Nepafenac还抑制了缺血引起的视网膜中VEGF mRNA的增加。在rho / VEGF转基因小鼠中,奈帕芬酸不能抑制新血管形成。在其他研究中,与用赋形剂治疗的小鼠相比,用0.1%或0.03%的奈帕芬酸治疗的小鼠的CNV明显更少,而用0.1%双氯芬酸治疗的眼睛则无显着差异。用0.5%酮咯酸三甲胺治疗14天的小鼠具有较高的死亡率,但在治疗7天后进行评估时,与用赋形剂治疗7天的小鼠无差异。结论:外用奈帕芬酸可通过降低VEGF的产生抑制CNV和局部缺血诱导的视网膜新生血管形成。在rho / VEGF转基因小鼠中没有作用与该机制一致。局部奈帕芬酸可能为眼新血管形成提供有效的新治疗方法。奈帕芬酸的出色角膜穿透力无疑在此作用中起着重要作用。在确定使角膜渗透最大化的制剂之后,其他抗血管生成剂也可能适合局部应用。由于局部递送途径具有许多优点,因此这是一个可能的探索主题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号